Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Issue 3 (1st March 2003)

• Record Type: Journal Article
• Authors: Stallmach, A; Wittig, B M; Moser, C; Fischinger, J; Duchmann, R; Zeitz, M
• Is Part Of: Gut. Volume 52:Issue 3(2003)
• Page Start: 377
• Page End: 382
• Publication Date: 2003-03-01
• Subjects: cyclophosphamide -- inflammatory bowel disease; IBD, inflammatory bowel disease -- TNF-α, tumour necrosis factor α -- CDAI, Crohn's disease activity index -- WBC, white blood cell -- SLE, systemic lupus erythematosus; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.52.3.377
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Background and aims: One major problem in the management of steroid refractory attacks of patients with inflammatory bowel disease (IBD) is the establishment of a rapidly acting immunosuppressive regimen. Based on its well known efficacy in systemic vasculitis, intravenous cyclophosphamide pulse therapy was used in refractory IBD patients to evaluate both its efficacy and safety. Methods: Between December 1998 and May 2001, seven patients (Crohn's disease, n=5; indeterminate colitis, n=1) with severe steroid refractory IBD (Crohn's disease activity index (CDAI) 264–479 points) received 4–6 cycles of monthly treatment with intravenous cyclophosphamide (750 mg) in a prospective uncontrolled pilot study. Results: All patients improved after two intravenous pulses of cyclophosphamide and six of seven patients achieved complete remission (CDAI <150 points). One patient with Crohn's disease of the small and large bowel showed an impressive clinical response but did not enter into remission. Tapering to low dose steroids was possible in all responders. Remission was maintained in all patients for 18 months (median) but required a second course of intravenous pulse cyclophosphamide in one patient. The drug was well tolerated except for two episodes of candida oesophagitis. Conclusions: Intravenous pulse cyclophosphamide may be a safe and effective treatment in patients with severe IBD unresponsive to steroid treatment and merits evaluation in a controlled trial.